Plasmodium falciparum dihydrofolate reductase-thymidylate synthase (DHFR-TS) is an established drug target of antimalarials such as pyrimethamine, which blocks the DHFR function. Basic studies on uptake of prodrugs and regulation of expression of DHFR-TS suggest that TS may also be a suitable target for malaria chemotherapy. This concept has received additional inspiration from the availability of the malaria DHFR-TS crystal structure and from vast efforts by pharmaceutical companies to develop medicinal chemistry against human TS for treatment of cancer. The central hypothesis of the present Program Project application is that folate-based TS inhibitors will be safe and effective for malaria chemotherapy when used in the presence of thymidine. The hypothesis rests on several key concepts and observations: POTENCY: Lead compounds display Ki approximately 1 nM for TS enzyme and EC50 below 100 nM against parasite cells. TARGET SPECIFICITY: As little as 10 mu M thymidine offers complete protection to mammalian cells. TARGET SPECIFICITY: In contrast, 10 mu M thymidine offers no protection to Plasmodium cells. SELECTIVITY VULNERABILITY: Malaria cells cannot overproduce DHFR-TS protein in response to antifolates. SELECTIVITY VULNERABILITY: There may be opportunities for malaria-specific TS binding. REDUCED DEVELOPMENT BARRIERS: Even without thymidine augmentation, several folate-based TS inhibitors have passed human Phase I, II, and III clinical trials for cancer treatment. The present Program Project has three specific aims: (i) To test a battery of TS inhibitors against P. falciparum for potency and emergence of resistance; (ii) To generate improved new TS inhibitors using structural and computational tools; and (iii) To measure efficacy and safety of TS inhibitors in mice and protective thymidine levels in humans. The team of established investigators offers highly complementary experiences ranging from physical biochemistry to malaria clinical trials in a U.S. hospital. Successful completion of this project will set the stage for testing malaria-specific TS inhibitors in humans and provide an exciting opportunity to take the uncommon step from basic science to the clinic with confidence.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program Projects (P01)
Project #
5P01AI060360-04
Application #
7273614
Study Section
Special Emphasis Panel (ZAI1-AC-M (J2))
Program Officer
Rogers, Martin J
Project Start
2004-07-01
Project End
2009-06-30
Budget Start
2007-07-01
Budget End
2008-06-30
Support Year
4
Fiscal Year
2007
Total Cost
$797,931
Indirect Cost
Name
University of Washington
Department
Chemistry
Type
Schools of Arts and Sciences
DUNS #
605799469
City
Seattle
State
WA
Country
United States
Zip Code
98195
Begley, Darren W; Zheng, Suxin; Varani, Gabriele (2010) Fragment-based discovery of novel thymidylate synthase leads by NMR screening and group epitope mapping. Chem Biol Drug Des 76:218-33
Pang, Cullen K T; Hunter, Joshua H; Gujjar, Ramesh et al. (2009) Catalytic and ligand-binding characteristics of Plasmodium falciparum serine hydroxymethyltransferase. Mol Biochem Parasitol 168:74-83
Gujjar, Ramesh; Marwaha, Alka; El Mazouni, Farah et al. (2009) Identification of a metabolically stable triazolopyrimidine-based dihydroorotate dehydrogenase inhibitor with antimalarial activity in mice. J Med Chem 52:1864-72
Mui, Ernest J; Schiehser, Guy A; Milhous, Wilbur K et al. (2008) Novel triazine JPC-2067-B inhibits Toxoplasma gondii in vitro and in vivo. PLoS Negl Trop Dis 2:e190
Hunter, Joshua H; Gujjar, Ramesh; Pang, Cullen K T et al. (2008) Kinetics and ligand-binding preferences of Mycobacterium tuberculosis thymidylate synthases, ThyA and ThyX. PLoS One 3:e2237
Ganesan, Karthikeyan; Ponmee, Napawan; Jiang, Lei et al. (2008) A genetically hard-wired metabolic transcriptome in Plasmodium falciparum fails to mount protective responses to lethal antifolates. PLoS Pathog 4:e1000214
Gonzales, Joseph M; Patel, Jigar J; Ponmee, Napawan et al. (2008) Regulatory hotspots in the malaria parasite genome dictate transcriptional variation. PLoS Biol 6:e238
Eastman, Richard T; White, John; Hucke, Oliver et al. (2007) Resistance mutations at the lipid substrate binding site of Plasmodium falciparum protein farnesyltransferase. Mol Biochem Parasitol 152:66-71
Mudeppa, Devaraja G; Pang, Cullen K T; Tsuboi, Takafumi et al. (2007) Cell-free production of functional Plasmodium falciparum dihydrofolate reductase-thymidylate synthase. Mol Biochem Parasitol 151:216-9
Hunt, Sonia Y; Detering, Carsten; Varani, Gabriele et al. (2005) Identification of the optimal third generation antifolate against P. falciparum and P. vivax. Mol Biochem Parasitol 144:198-205

Showing the most recent 10 out of 13 publications